Navigation Links
Iressa as Good as Chemotherapy for Lung Cancer
Date:11/21/2008

Daily pill easier to take, has fewer side effects than chemotherapy, experts say

FRIDAY, Nov. 21 (HealthDay News) -- The cancer-fighting pill Iressa works as well as chemotherapy as a second-line treatment for lung cancer, researchers report.

Although neither therapy prolongs survival beyond eight months, Iressa (gefitinib) causes fewer serious side effects and may be a better choice for patients who did not do well on their first round of chemotherapy.

"A pill, with less side effects, taken once a day, has similar activity to traditional chemotherapy given by vein every three weeks," said lead researcher Dr. Edward Kim, an assistant professor at the M. D. Anderson Cancer Center in Houston.

This finding should reassure doctors that they are not compromising effective therapy by using a pill, Kim said.

Iressa is not available in the United States, but a similar drug, Tarceva, is.

Iressa was first developed by AstraZeneca, but it failed to meet expectations. The National Cancer Institute ended clinical trials of the drug in 2005 because it failed to prolong the lives of lung cancer patients.

The latest finding has meaning for these patients, however, Kim said. "You can be treated for lung cancer. There are different therapies available, and they have different side-effect profiles," he said. "Chemotherapy will never be eliminated, but we are getting more options for targeted therapy; and people can live as normal a life as they can bearing the weight of lung cancer."

The report was published in the Nov. 22 issue of The Lancet.

In a head-to-head comparison, Kim's team randomly assigned 1,466 lung cancer patients who had undergone previous chemotherapy to daily doses of Iressa or the chemotherapy drug docetaxel once every three weeks.

The researchers found that survival in both groups of patients was about the same. Median survival for those taking Iressa was 7.6 months compared with eight months for patients receiving docetaxel. For patients with an EFGR gene mutation, average survival was 8.4 months for those on Iressa and 7.5 months for those receiving docetaxel.

However, there were significant differences in the side effects experienced by the treatment groups. For patients taking Iressa, the most common side effects were rash or acne. Among patients receiving docetaxel, the most common side effects were a blood disorder called neutropenia, personality disorders, and hair loss.

Dr. Michael Cullen, from the University Hospital Birmingham in the United Kingdom and author of an accompanying journal comment, noted that Iressa works differently than chemotherapy by targeting a receptor that is present in some patient's cancer cells.

"There are now two options that one can select from for patients in order to offer treatment that helps a bit following failure of first-line chemotherapy," Cullen said. "Survival overall is very poor, and, in fact, it's almost certainly the case that only a small minority of patients respond to either of the two treatments."

In addition, which patients would benefit most from Iressa isn't known, Cullen said. "In the study, tests didn't indicate that we are able to select treatment based on different characteristics of the patient."

Because survival time is short, Cullen thinks that doctors may want to decide which treatment to use based on how well a patient tolerated chemotherapy before.

"If they didn't tolerate chemotherapy very well, maybe the oncologist would opt for the oral therapy, whereas if they responded well to chemotherapy, the best choice might be to go with the chemotherapy," Cullen said.

More information

For more on lung cancer, visit the U.S. National Cancer Institute.



SOURCES: Edward Kim, M.D., assistant professor, M. D. Anderson Cancer Center, Houston; Michael Cullen, M.D., University Hospital Birmingham, U.K.; Nov. 22, 2008, The Lancet


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
2. Chemotherapy may be culprit for fatigue in breast cancer survivors
3. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
4. To evade chemotherapy, some cancer cells mimic stem cells
5. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
6. PET scans can accurately detect a breast tumors response to chemotherapy
7. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
8. Medicare modernization act did not change chemotherapy as feared
9. HER-2 status predicts success of chemotherapy in breast cancer treatment, study finds
10. Cancer conflict with chemotherapy treatment
11. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Iressa as Good as Chemotherapy for Lung Cancer
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Restoration, has recently contributed a medical article to the newly revamped Cosmetic ... Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... of $3,296 in property taxes a year. In some states—like New York, New ... , By contrast, many overseas retirement havens have extremely low property-tax rates, which ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sciences content management, presents its enhanced Pepper Flow promotional review platform at ... 2017. Pepper Flow’s increased insight-driven capabilities help marketers streamline the medical, legal, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017 Halo Labs announces the European launch of their ... HORIZON at MIBio 2017 in Cambridge, U.K ... matter in biopharmaceutical samples with unprecedented speed and sensitivity while using ... Backgrounded Membrane Imaging. ... subvisible particle analysis system ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
Breaking Medicine Technology: